Maternal deaths from anaesthesia. An extract from Why Mothers Die 1997–1999 , the Confidential Enquiries into Maternal Deaths in the United Kingdom

Abstract

This article is reprinted from Why Mothers Die 1997-1999, the fifth report of the Confidential Enquiries into Maternal Deaths in the United Kingdom.

ST depression at caesarean section and the relation to oxytocin dose. A randomised controlled trial

“…Excessive blood loss is more likely during intrapartum caesareans and oxytocin could be detrimental to women who are hypovolemic. 11,15,[17][18][19] It is reasonable to assume that ST-depressions are as common during intrapartum caesareans and the clinical significance of our results could be more important within such circumstances.…”

“…15,16 Oxytocin could be detrimental to women who are hypovolemic and to women with cardiac disease. 11,15,[17][18][19] As oxytocin has dose-dependent adverse effects, we were interested in finding out whether there are any differences in the rate of ECG changes indicating myocardial ischaemia (ECG depression) between two different doses of oxytocin.…”

Preeclampsia induced cardiopulmonary arrest in pregnant: a case report

“…[1] Preeklampsi nulliparite, çoklu gebelik, diabetes mellitus, kronik hipertansiyon, böbrek hastalıkları ve antifosfolipid antikor hastalığı gibi hastalıkların risk faktörü olduğu yaygın bir gebelik komplikasyonudur. [2] Preeklampsi, gebelerdeki hipertansiyon (sistolik kan basıncı >140 mmHg veya diyastolik basınç >90 mmHg) ve proteinü-ri (>300 mg/24 saat) ile tanımlanır.…”

Pharmacologic intervention for managing uterine atony and related maternal hemorrhage: what is the most effective drug dose?

“…In 2002, a review of anesthesia-related causes of maternal death in the United Kingdom from 1997-1999 highlighted the adverse effects of bolus administration of oxytocin and prompted a number of studies to evaluate all effective dose (ED)90 for bolus administration of oxytocin. 7 Canadian investigators led the way. 8,9 These investigations suggested that an ED90 bolus dose of 0.35 U is efficacious, much lower than the traditional 5-10 U.…”

“…En 2002, un compte rendu examinant les causes de décès maternels liées à l'anesthésie au Royaume-Uni entre 1997 et 1999 a tiré la sonnette d'alarme concernant les effets défavorables de l'administration d'un bolus d'oxytocine; à la suite de ce compte rendu, plusieurs études ont été menées afin d'évaluer la dose efficace (DE)90 pour l'administration de bolus d'oxytocine. 7 Des chercheurs canadiens ont d'ailleurs ouvert le chemin. 8,9 Ces recherches ont abouti à la proposition d'une DE90 de 0,35 IU comme bolus efficace, une quantité bien plus faible que les 5-10 IU conventionnellement administrés.…”